Published in Biosens Bioelectron on April 16, 2009
Implantable magnetic relaxation sensors measure cumulative exposure to cardiac biomarkers. Nat Biotechnol (2011) 1.69
Magnetic nanoparticle sensors. Sensors (Basel) (2009) 1.35
Nanotechnology for early cancer detection. Sensors (Basel) (2010) 1.01
Novel molecular and nanosensors for in vivo sensing. Theranostics (2013) 0.89
Particles and microfluidics merged: perspectives of highly sensitive diagnostic detection. Mikrochim Acta (2012) 0.79
Strategic workshops on cancer nanotechnology. Cancer Res (2010) 0.77
Homogeneous Biosensing Based on Magnetic Particle Labels. Sensors (Basel) (2016) 0.75
Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol (2000) 6.90
High-efficiency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates. Bioconjug Chem (1999) 4.41
Magnetic relaxation switches capable of sensing molecular interactions. Nat Biotechnol (2002) 4.13
Protein drug stability: a formulation challenge. Nat Rev Drug Discov (2005) 2.51
Characterization of implantable biosensor membrane biofouling. Fresenius J Anal Chem (2001) 1.92
Diagnostic accuracy of 201Thallium-SPECT and 18F-FDG-PET in the clinical assessment of glioma recurrence. Eur J Nucl Med Mol Imaging (2008) 1.55
Applicability of intraoperative parathyroid hormone assay during thyroidectomy. Ann Surg (2002) 1.26
Chronic, programmed polypeptide delivery from an implanted, multireservoir microchip device. Nat Biotechnol (2006) 1.18
Sentinel lymph node as a target of molecular diagnosis of lymphatic micrometastasis and local immunoresponse to malignant cells. Cancer Sci (2007) 1.16
Magnetic relaxation switch detection of human chorionic gonadotrophin. Bioconjug Chem (2007) 1.13
Multi-reservoir device for detecting a soluble cancer biomarker. Lab Chip (2007) 1.09
Continuous analyte sensing with magnetic nanoswitches. Small (2006) 1.07
Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. Gynecol Oncol (2007) 1.03
Clinical uses of tumor markers: a critical review. Crit Rev Clin Lab Sci (2001) 1.02
Rapid intraoperative immunoassay of parathyroid hormone and other hormones: a new paradigm for point-of-care testing. Clin Chem (2004) 1.01
Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev (2005) 1.01
Early identification of resistance to first-line single-agent methotrexate in patients with persistent trophoblastic disease. J Clin Oncol (2006) 0.97
Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers. Expert Rev Mol Diagn (2007) 0.95
(201)Tl-SPECT in low-grade gliomas: diagnostic accuracy in differential diagnosis between tumour recurrence and radionecrosis. Eur J Nucl Med Mol Imaging (2004) 0.93
Immunoreactive human chorionic gonadotropin and its free beta subunit in serum and ascites of patients with malignant tumors. Cancer Res (1992) 0.82
Measurement of human chorionic gonadotropin-related immunoreactivity in serum, ascites and tumour cysts of patients with gynaecologic malignancies. Eur J Clin Invest (1995) 0.82
Considerations on the use of diagnostic markers in management of patients with bladder cancer. World J Urol (2007) 0.81
Exploration of metastasis-related proteins as biomarkers and therapeutic targets in the treatment of head and neck cancer. Curr Cancer Drug Targets (2007) 0.79
Structure and activity assay of nanozymes prepared by the coimmobilization of practically useful enzymes and hydrophilic block copolymers on gold nanoparticles. Langmuir (2008) 0.79
Surface treatment of polycarbonate films aimed at biomedical application. J Biomater Sci Polym Ed (2003) 0.78
Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol (2007) 17.80
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med (2008) 14.47
Restoration of p53 function leads to tumour regression in vivo. Nature (2007) 12.62
Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov (2009) 12.46
The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med (2007) 11.51
Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science (2009) 10.47
Looking and listening to light: the evolution of whole-body photonic imaging. Nat Biotechnol (2005) 9.57
Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med (2003) 9.09
Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest (2007) 8.65
Engineering vascularized skeletal muscle tissue. Nat Biotechnol (2005) 7.73
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell (2012) 7.36
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A (2006) 6.90
Impact of nanotechnology on drug delivery. ACS Nano (2009) 6.87
A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol (2008) 6.81
Microscale technologies for tissue engineering and biology. Proc Natl Acad Sci U S A (2006) 6.66
Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging. Eur Radiol (2002) 6.06
Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo. Mol Ther (2005) 6.04
Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med (2012) 5.92
Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci U S A (2006) 5.90
Fluorescence molecular tomography resolves protease activity in vivo. Nat Med (2002) 5.53
Nanoliter-scale synthesis of arrayed biomaterials and application to human embryonic stem cells. Nat Biotechnol (2004) 5.51
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell (2006) 5.34
Arthritis critically dependent on innate immune system players. Immunity (2002) 5.31
Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell (2002) 5.11
The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha. Cell (2010) 5.11
Transdermal drug delivery. Nat Biotechnol (2008) 5.11
Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci U S A (2002) 4.77
Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A (2008) 4.57
Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res (2004) 4.56
Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol (2005) 4.55
Myocardial infarction accelerates atherosclerosis. Nature (2012) 4.48
Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol (2008) 4.46
A tough biodegradable elastomer. Nat Biotechnol (2002) 4.35
Chip-NMR biosensor for detection and molecular analysis of cells. Nat Med (2008) 4.29
Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci U S A (2010) 4.25
Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging in vivo. Circulation (2007) 4.20
Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat Med (2013) 4.14
Magnetic relaxation switches capable of sensing molecular interactions. Nat Biotechnol (2002) 4.13
Functional assembly of engineered myocardium by electrical stimulation of cardiac myocytes cultured on scaffolds. Proc Natl Acad Sci U S A (2004) 4.13
Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci U S A (2004) 4.12
Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nat Med (2012) 4.11
Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials (2006) 4.09
Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis. J Gene Med (2005) 4.04
Accordion-like honeycombs for tissue engineering of cardiac anisotropy. Nat Mater (2008) 4.00
A reversibly switching surface. Science (2003) 3.97
A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat Med (2007) 3.96
Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol (2011) 3.95
Tetrazine-based cycloadditions: application to pretargeted live cell imaging. Bioconjug Chem (2008) 3.93
Regulatory T cells reversibly suppress cytotoxic T cell function independent of effector differentiation. Immunity (2006) 3.92
Small-scale systems for in vivo drug delivery. Nat Biotechnol (2003) 3.90
Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation (2007) 3.85
Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci U S A (2008) 3.80
Nanoparticle delivery of cancer drugs. Annu Rev Med (2011) 3.75
Endothelial cells derived from human embryonic stem cells. Proc Natl Acad Sci U S A (2002) 3.66
Fast and sensitive pretargeted labeling of cancer cells through a tetrazine/trans-cyclooctene cycloaddition. Angew Chem Int Ed Engl (2009) 3.63
Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci U S A (2008) 3.62
Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation (2006) 3.57
First-in-human testing of a wirelessly controlled drug delivery microchip. Sci Transl Med (2012) 3.56
Multimodality molecular imaging identifies proteolytic and osteogenic activities in early aortic valve disease. Circulation (2007) 3.51
Molecular imaging in drug discovery and development. Nat Rev Drug Discov (2003) 3.44
Controlled degradation and mechanical behavior of photopolymerized hyaluronic acid networks. Biomacromolecules (2005) 3.44
Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov (2004) 3.41
Monocyte accumulation in mouse atherogenesis is progressive and proportional to extent of disease. Proc Natl Acad Sci U S A (2006) 3.38
Oncomodulin is a macrophage-derived signal for axon regeneration in retinal ganglion cells. Nat Neurosci (2006) 3.35
Functional recovery following traumatic spinal cord injury mediated by a unique polymer scaffold seeded with neural stem cells. Proc Natl Acad Sci U S A (2002) 3.35
Multifunctional magnetic nanoparticles for targeted imaging and therapy. Adv Drug Deliv Rev (2008) 3.34
A secreted luciferase for ex vivo monitoring of in vivo processes. Nat Methods (2008) 3.31
Treating metastatic cancer with nanotechnology. Nat Rev Cancer (2011) 3.30
Hyaluronic acid hydrogel for controlled self-renewal and differentiation of human embryonic stem cells. Proc Natl Acad Sci U S A (2007) 3.19
Intravital imaging. Cell (2011) 3.18
Outbreak of adverse reactions associated with contaminated heparin. N Engl J Med (2008) 3.16
Nanotechnological strategies for engineering complex tissues. Nat Nanotechnol (2010) 3.15
Combinatorial development of biomaterials for clonal growth of human pluripotent stem cells. Nat Mater (2010) 3.11
Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery. Nat Nanotechnol (2012) 3.09
Engineering substrate topography at the micro- and nanoscale to control cell function. Angew Chem Int Ed Engl (2009) 3.09
Rapid monocyte kinetics in acute myocardial infarction are sustained by extramedullary monocytopoiesis. J Exp Med (2012) 2.92
Multivalent effects of RGD peptides obtained by nanoparticle display. J Med Chem (2006) 2.91
MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas. Cancer Res (2007) 2.90
Impaired infarct healing in atherosclerotic mice with Ly-6C(hi) monocytosis. J Am Coll Cardiol (2010) 2.90
Near-infrared fluorescence: application to in vivo molecular imaging. Curr Opin Chem Biol (2009) 2.89
Microengineered hydrogels for tissue engineering. Biomaterials (2007) 2.87
Differentiation of human embryonic stem cells on three-dimensional polymer scaffolds. Proc Natl Acad Sci U S A (2003) 2.86
An X-ray computed tomography imaging agent based on long-circulating bismuth sulphide nanoparticles. Nat Mater (2006) 2.84
Semi-automated synthesis and screening of a large library of degradable cationic polymers for gene delivery. Angew Chem Int Ed Engl (2003) 2.83
Ultrasensitive clinical enumeration of rare cells ex vivo using a micro-hall detector. Sci Transl Med (2012) 2.82
The inflammatory responses to silk films in vitro and in vivo. Biomaterials (2005) 2.79
Biodegradable, elastic shape-memory polymers for potential biomedical applications. Science (2002) 2.79
The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. Cell (2012) 2.78
Dual channel optical tomographic imaging of leukocyte recruitment and protease activity in the healing myocardial infarct. Circ Res (2007) 2.77
Visualization of antitumor treatment by means of fluorescence molecular tomography with an annexin V-Cy5.5 conjugate. Proc Natl Acad Sci U S A (2004) 2.77
Self-assembled lipid--polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano (2008) 2.76
Rapid detection and profiling of cancer cells in fine-needle aspirates. Proc Natl Acad Sci U S A (2009) 2.75
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci U S A (2006) 2.72
Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv Drug Deliv Rev (2006) 2.69
Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ Res (2005) 2.67